Product Information
TGR 1202 is a monoclonal antibody that modulates the immune system. It has been shown to inhibit the activation of PI3K-δ, which plays a role in T-cell lymphomas and hematologic response. TGR 1202 also has minimal toxicity, with no adverse effects seen at doses up to 1.5 mg/kg in vivo. TGR 1202 binds to receptors on lymphocytes, leading to cell apoptosis and inhibition of proliferation. The drug is active against monoclonal antibody-resistant leukemic mice and has synergistic effects when used with other drugs like ibrutinib or lenalidomide. Pharmacokinetic properties have been studied in mice, dogs, and monkeys.
TGR 1202 shows good pharmacokinetics in vivo, with a half-life of about 10 hours in mice, dogs, and monkeys.
Chemical properties
Technical inquiry about: 3D-FT171036 TGR 1202
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
